Literature DB >> 3143577

Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.

M J Haverkorn1.   

Abstract

Forty-two patients with respiratory tract infection caused by Pseudomonas aeruginosa were treated with 500 mg ciprofloxacin administered orally twice daily. Pseudomonas aeruginosa was eradicated in 22 patients but recurred in eight patients. Clinical improvement or resolution was noted in 37 patients (88%). Eradication and cure rates were highest in patients without permanent risk factors, and in patients with hospital-acquired infection. New colonization during treatment was noted in 14 patients (33%), but no superinfection occurred. In persisting strains of Pseudomonas aeruginosa the in vitro sensitivity to ciprofloxacin decreased significantly during therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143577     DOI: 10.1007/bf01964247

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Penetration of ciprofloxacin into human lung tissue following intravenous injection.

Authors:  D Schlenkhoff; A Dalhoff; J Knopf; W Opferkuch
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

2.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

3.  Ciprofloxacin penetration into lungs.

Authors:  D Honeybourne; R Wise; J M Andrews
Journal:  Lancet       Date:  1987-05-02       Impact factor: 79.321

4.  Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.

Authors:  M J Smith; L O White; H Bowyer; J Willis; M E Hodson; J C Batten
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

6.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

7.  Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan.

Authors:  H Kobayashi
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

9.  Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  F Follath; M Bindschedler; M Wenk; R Frei; H Stalder; H Reber
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

10.  Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  H Giamarellou; N Galanakis; C Dendrinos; J Stefanou; E Daphnis; G K Daikos
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

  10 in total
  6 in total

1.  Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

Authors:  A L Barry; P C Fuchs; M A Pfaller; S D Allen; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

Authors:  M López-Brea; T Alarcón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

3.  Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.

Authors:  D Desgrandchamps; J Munzinger
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

4.  Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.

Authors:  E Ulrich; M Trautmann; B Krause; A Bauernfeind; H Hahn
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

5.  Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group.

Authors:  F Alvarez-Lerma
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

6.  Two different dosages of ciprofloxacin in patients with respiratory tract infections.

Authors:  T Brutel de la Rivière; M S Daniëls-Bosman; G P ten Velde
Journal:  Pharm Weekbl Sci       Date:  1989-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.